Transitional Cell Carcinoma: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Transitional Cell Carcinoma or TCC is a rare form of [[Cancer|cancer]]. This [[Cancer|cancer]] occurs in the [[Transitional cells|transitional cells]] that line the [[Ureter|ureter]] and the [[Renal pelvis|renal pelvis]] of the [[Kidneys|kidneys]]<ref>https://www.healthline.com/health/cancer-renal-pelvis-or-ureter Written by Darla Burke and Medically reviewed by Christina Chun MPH Feb 22 2018 [accessed: 19/10/18]</ref>. Like all [[Cancer|cancers]] these [[Tumour|tumours are]] graded - depending upon the grade of [[Cancer|cancer]] in the patient determines methodology of [[Treatment|treatments]] or potentially a combination of[[Treatment|treatments]] against the[[Tumour|tumour]]. Patients with a grade 1 or 2 [[Tumour|tumour]] are more likely to survive with an intervention of [[Treatment|treatment]] compared to patients who have a grade 3 or 4 [[Tumour|tumour]]<sup></sup><ref>https://www.sciencedirect.com/science/article/pii/S0090429598002957 Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients M.Craig Hall Sean Womack Arthur I Sagalowsky Thomas Carmody Mark D Erickstad Claus G Roehrborn Urology Volume 52, Issue 4, October 1998, Pages 594-601 [accessed: 19/10/18]</ref>. | |||
== Treatment == | |||
---- | There are several [[Treatment|treatment]] options available to those with low-grade TCC tumours, while several other treatment options are currently undergoing [[Clinical trials|clinical trials]]. The most common treatment offered is; [[Surgery|surgery]]. [[Surgery|Surgery]] further subdivides into two different forms which are dependent upon size and location of the [[Tumour|tumour]]. In many cases, a [[Nephroureterectomy|nephroureterectomy]] will be performed in which a majority of the [[Urinary tract|urinary tract]] will be removed in order to prevent localised spreading or growth of the [[Tumour|tumour]]. However if the tumour is smaller and more localised within the [[Renal pelvis|renal pelvis]] then a [[Segmental resection|segmental resection]] may be the more favoured procedure as this removes the section of the [[Kidney|kidney]] that contains the [[Malignant tumour|malignant tumour]] as well as a small surrounding area of viable cells in order to also prevent localised growth and spreading<sup></sup><ref>https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq#section/_46 Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version [Accessed: 19/10/18]</ref>. | ||
Several [[Treatment|treatments]] that are currently under [[Clinical trials|clinical trial]] range from [[Laser surgery|laser surgery]] to [[Chemotherapy|chemotherapy]] paired with [[Biologic therapy|biologic therapy]]. These new[[Therapy|therapies]] and [[Treatment|treatments]] are designed to be more precise in destroying [[Cancer cells|cancer cells within]] the [[Organ|organ]] and aim at using other methods rather than classic invasive [[Surgery|surgery]] that is currently used. There has been [[Research|research]] into the use of electric currents and laser beams in order to accurately target [[Cancerous cells|cancerous cells]] leaving behind more healthy viable cells in the process<ref>https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq#section/_46 Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version [Accessed: 19/10/18]</ref>. [[Clinical trials|Clinical trial]] treatments are usually offered to patients with later stages of [[Cancer|cancer]] such as stage 3 or 4. | |||
= | === References === | ||
<references /> | <references /> | ||
Latest revision as of 07:45, 20 October 2018
Transitional Cell Carcinoma or TCC is a rare form of cancer. This cancer occurs in the transitional cells that line the ureter and the renal pelvis of the kidneys[1]. Like all cancers these tumours are graded - depending upon the grade of cancer in the patient determines methodology of treatments or potentially a combination oftreatments against thetumour. Patients with a grade 1 or 2 tumour are more likely to survive with an intervention of treatment compared to patients who have a grade 3 or 4 tumour[2].
Treatment
There are several treatment options available to those with low-grade TCC tumours, while several other treatment options are currently undergoing clinical trials. The most common treatment offered is; surgery. Surgery further subdivides into two different forms which are dependent upon size and location of the tumour. In many cases, a nephroureterectomy will be performed in which a majority of the urinary tract will be removed in order to prevent localised spreading or growth of the tumour. However if the tumour is smaller and more localised within the renal pelvis then a segmental resection may be the more favoured procedure as this removes the section of the kidney that contains the malignant tumour as well as a small surrounding area of viable cells in order to also prevent localised growth and spreading[3].
Several treatments that are currently under clinical trial range from laser surgery to chemotherapy paired with biologic therapy. These newtherapies and treatments are designed to be more precise in destroying cancer cells within the organ and aim at using other methods rather than classic invasive surgery that is currently used. There has been research into the use of electric currents and laser beams in order to accurately target cancerous cells leaving behind more healthy viable cells in the process[4]. Clinical trial treatments are usually offered to patients with later stages of cancer such as stage 3 or 4.
References
- ↑ https://www.healthline.com/health/cancer-renal-pelvis-or-ureter Written by Darla Burke and Medically reviewed by Christina Chun MPH Feb 22 2018 [accessed: 19/10/18]
- ↑ https://www.sciencedirect.com/science/article/pii/S0090429598002957 Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients M.Craig Hall Sean Womack Arthur I Sagalowsky Thomas Carmody Mark D Erickstad Claus G Roehrborn Urology Volume 52, Issue 4, October 1998, Pages 594-601 [accessed: 19/10/18]
- ↑ https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq#section/_46 Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version [Accessed: 19/10/18]
- ↑ https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq#section/_46 Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version [Accessed: 19/10/18]